Core Insights - Adagene Inc. is set to present its lead clinical program, muzastotug, at the AACR Meeting in April 2026, highlighting its potential in cancer immunotherapy [1][4] Group 1: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [2] - The company has established strategic collaborations to leverage its SAFEbody precision masking technology, aiming to address unmet patient needs in cancer treatment [2] Group 2: Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, which are designed to enhance the safety and efficacy of antibody therapeutics [3] - The SAFEbody technology specifically targets safety and tolerability challenges by masking the binding domain of biologic therapies, allowing for tumor-specific targeting while minimizing off-tumor toxicity [3] Group 3: Clinical Programs - Muzastotug (ADG126) is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, currently undergoing Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy for microsatellite stable metastatic colorectal cancer [4] - The SAFEbody platform is validated for use across various antibody-based therapeutic modalities, including Fc empowered antibodies and antibody-drug conjugates [4]

Core Insights - Adagene Inc. is participating in two upcoming healthcare conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Global Healthcare Conference from March 8-11, 2026 [1][2] - The company recently presented at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, with a webcast available for viewing [3] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [4] - The company has established strategic collaborations leveraging its SAFEbody precision masking technology to address unmet patient needs in cancer treatment [4] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, which are designed to enhance the safety and efficacy of antibody therapeutics [5] - The lead clinical program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, currently in Phase 1b/2 and Phase 2 studies targeting microsatellite stable metastatic colorectal cancer [6]

Core Insights - Adagene Inc. announced an update on its ongoing Phase 1b/2 study of muzastotug in combination with pembrolizumab for patients with microsatellite stable metastatic colorectal cancer (MSS CRC), with data expected in Q1 2026 [1][6] - The company reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, which is anticipated to provide sufficient runway until late 2027 [1][3] 2025 Key Accomplishments - The company demonstrated a favorable safety profile for muzastotug at doses 10-20 times higher than first-generation CTLA-4 inhibitors, with encouraging overall response rates and durable responses [5] - Muzastotug received FDA Fast Track designation for use in combination with KEYTRUDA for adult patients with MSS CRC without current or active liver metastases [5] - Adagene secured a strategic investment of up to $25 million from Sanofi to support the randomized Phase 2 study of muzastotug [5] - Collaborations were established with Third Arc Bio for developing next-generation T cell therapies and with Exelixis for advancing a third masked ADC against a solid tumor target [5] 2026 Objectives - The company aims to provide a data update from the ongoing Phase 1b/2 study, including results from 41 patients in the 10 mg/kg cohort and 26 patients in the 20 mg/kg cohort [6] - Complete enrollment of the randomized Phase 2 dose-optimization study with muzastotug, aligned with FDA Project Optimus [6] - Share results from a clinical trial collaboration with Roche evaluating muzastotug in combination with atezolizumab and bevacizumab for liver cancer [6] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [8] - The company's lead clinical program, muzastotug, is a masked anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment, currently in Phase 1b/2 and Phase 2 studies [10]

Core Insights - Adagene Inc. (ADAG) received Fast Track designation from the FDA for its lead immuno-oncology candidate, muzastotug (ADG126), in combination with Merck's Keytruda for treating adult patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC) without active liver metastases [1][6] - Following the announcement, ADAG shares increased by 13.8% [1][7] - The Fast Track designation aims to expedite the development and review of therapies for serious diseases with unmet medical needs [2] Company Overview - Muzastotug is a next-generation anti-CTLA-4 antibody developed using proprietary SAFEbody masking technology, which may improve survival and quality of life compared to conventional therapies [5][7] - The ongoing phase II study has primary and secondary endpoints focused on overall response rate, duration of response, progression-free survival, and overall survival [6][8] - A phase III study is planned to start in 2027, contingent on continued positive clinical results [8] Market Performance - Over the past year, ADAG's shares have declined by 6.9%, contrasting with a 16.3% rise in the industry [4] - The Fast Track designation allows for more frequent interactions with the FDA and potential rolling reviews of future marketing applications [8]

Core Insights - The FDA has granted Fast Track Designation to Adagene's muzastotug in combination with Merck's KEYTRUDA® for treating adult patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) without active liver metastases, highlighting the potential of this therapy to meet an unmet medical need [1][2][3] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence to create innovative therapies [4][7] - The company employs its proprietary SAFEbody technology to enhance the safety and efficacy of antibody therapies by targeting the tumor microenvironment while minimizing systemic toxicity [6][7] Clinical Development - Muzastotug is a next-generation masked anti-CTLA-4 SAFEbody designed to overcome Treg resistance in tumors, showing promising efficacy and safety in heavily pretreated patient populations [2][3] - The ongoing Phase 2 trial will evaluate muzastotug in combination with pembrolizumab, with a focus on late-line patients with MSS CRC without liver metastases [5][7] - The primary endpoint for the Phase 2 trial is overall response rate (ORR), while the Phase 3 trial will focus on overall survival (OS) as the primary endpoint [5] Future Plans - Adagene plans to share updated topline Phase 1b/2 clinical data in the coming months and is preparing for a registration trial set to begin in 2027 [3][5]

Core Insights - Adagene Inc. has initiated a Phase 2 clinical trial for muzastotug in combination with KEYTRUDA for patients with microsatellite stable colorectal cancer, with the first patient dosed in October 2025 [1][2] - The trial aims to confirm the optimal dosing for a subsequent Phase 3 trial, with completion anticipated in early 2027 and potential updates expected in 2026 [1][2] Phase 2 Clinical Trial Details - The trial will randomize patients to receive either 10 mg/kg or 20 mg/kg of muzastotug, with up to 30 patients per arm [1][4] - The primary endpoint is overall response rate (ORR), while secondary endpoints include duration of response (DOR), progression-free survival (PFS), and overall survival (OS) [4] Phase 1b/2 Trial Findings - In the Phase 1b/2 trial, 67 patients were treated with muzastotug, showing an ORR of 17% for the 10 mg/kg cohort and 29% for the 20 mg/kg cohort [3][4] - The median duration of response for the 10 mg/kg cohort was 6.2 months, while the median overall survival for the 10 mg/kg cohort was 19.4 months [5] Safety Profile - Muzastotug has been safely dosed at 20 mg/kg with less than 20% Grade 3 adverse events and no discontinuations, indicating a favorable safety profile compared to first-generation anti-CTLA-4 therapies [2][5] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [7][8] - The company's lead program, ADG126 (muzastotug), targets regulatory T cells in the tumor microenvironment and is part of a broader pipeline leveraging its SAFEbody technology [9]

Core Insights - Adagene Inc. has received FDA feedback on its clinical development plan for ADG126 in combination with Merck's KEYTRUDA for treating microsatellite stable colorectal cancer [2][4] - The company plans to begin patient enrollment for Phase 2 trials in the second half of 2025 [1] Company Overview - Adagene is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using its SAFEbody technology [7][10] - The company's lead program, ADG126, is designed to target regulatory T cells in the tumor microenvironment [10] Clinical Development - ADG126 is currently in Phase 1b/2 clinical studies, with over 150 patients enrolled to date [3][10] - The Phase 2 trial will randomize patients to receive either 10 mg/kg or 20 mg/kg of ADG126 in combination with pembrolizumab, without cycle limitations [7] - The primary endpoint for the Phase 2 trial is overall response rate (ORR), with secondary endpoints including duration of response (DOR), progression-free survival (PFS), and overall survival (OS) [7] FDA Interaction - The FDA has endorsed the exploration of ADG126 at doses significantly higher than other anti-CTLA-4 antibodies, showing a nearly two-fold increase in ORR from 17% at 10 mg/kg to 29% at 20 mg/kg [5][6] - The FDA has agreed with the proposed standard-of-care control arm for the Phase 3 trial, confirming that an ADG126 monotherapy arm is not required [7] Future Directions - The company aims to identify a single optimized dose for the Phase 3 trial, which is a critical step towards obtaining FDA approval [6][7] - Future trials will focus on late-line patients with MSS CRC without liver metastases [7]

Core Insights - Sanofi has made a strategic investment of up to US$25 million in Adagene to support the development of novel antibody-based therapies, particularly focusing on the clinical development of muzastotug (ADG126) for colorectal cancer [3][6] - Adagene will provide Sanofi with muzastotug for a phase 1/2 clinical trial involving over 100 patients to evaluate its safety and efficacy in combination with other anticancer therapies [4][6] - The partnership includes the exercise of an option for a third SAFEbody discovery program, which will utilize Adagene's proprietary technology [5][6] Financial Overview - The proceeds from Sanofi's investment, along with Adagene's existing cash and cash equivalents of US$85.2 million as of December 31, 2024, are expected to fund operations into 2027 [6] Clinical Development - Adagene's lead clinical program, ADG126, is currently in phase 1b/2 studies, targeting metastatic microsatellite-stable colorectal cancer [10] - The SAFEbody technology aims to enhance safety and tolerability in antibody therapeutics by using precision masking to minimize off-target toxicity [9][10] Strategic Collaboration - A representative from Sanofi will join Adagene's Scientific Advisory Board to provide strategic advice on scientific and clinical aspects [7] - The collaboration reinforces the shared vision of advancing ADG126's potential in treating advanced solid tumors [6]